Warsaw Orthopedic, Inc.

Osteotech, Inc.

David Knaack

John Winterbottom

Lawrence A Shimp

Todd M Boyce

David R Kaes

Deger C Tunc

Subhabrata Bhattacharyya

James L Russell

Keyvan Behnam

Nanette Forsyth

Kathy Traianedes

Michele Diegman

Randal R Betz

John W Morris

Albert Manrique

Jo-Wen Lin

Michele Diegmann

Perry Geremakis

Robert Waterman

Robert P Skinner

Keyvan Benham

Larry Shimp

Jennifer Grasso

John M Winterbottom

An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors, such as may be extracted from demineralized bone, and a carrier. The osteoinductive composition is prepared by providing demineralized bone, extracting osteoinductive factors from the demineralized bone, and adding the extracted osteoinductive factors to a carrier. Further additives such as bioactive agents may be added to the osteoinductive composition. The carrier and osteoinductive factors may form an osteogenic osteoimplant. The osteoimplant, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation including vascularization, mineralization, and bone marrow differentiation. Also, in some embodiments, the osteoinductive composition can be used as a delivery device to administer bioactive agents.

Bone matrix compositions and methods

Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.

Polyurethanes for osteoimplants

An osteoimplant composite comprising a plurality of particles of an inorganic material, a bone substitute material, a bone-derived material, or any combination thereof; and a polymer material with which the particles are combined. The composite is either naturally moldable or flowable, or it can be made moldable or settable. After implantation, the composite may be set to provide mechanical strength to the implant. The inventive composite have the advantage of being able to fill irregularly shape implantation site while at the same time being settable to provide the mechanical strength required for most orthopedic applications. The invention also provides methods of using and preparing the moldable and flowable composites.

Injectable and moldable bone substitute materials

A method of producing a bone-polymer composite. The method comprises the steps of providing a plurality of bone particles, combining the bone particles with a polymer precursor, and polymerizing the polymer precursor.

Synthesis of a bone-polymer composite material

An implant including a substantially cohesive aggregate comprising bone-derived particles. Cohesiveness is maintained by a member of mechanical interlocking, engagement of adjacent bone-derived particles with one another through engagement with a binding agent, thermal bonding, chemical bonding, or a matrix material in which the bone-derived particles are retained. The aggregate is shaped as a one-dimensional or two-dimensional body.

Tissue-derived mesh for orthopedic regeneration

The invention provides a method for the preparation of bone-polymer composites wherein the mineral portion of the bone is treated with a coupling agent before being incorporated into a biocompatible polymeric matrix. The resulting composites may be used as such or be further processed to form an osteoimplant.

Coupling agents for orthopedic biomaterials

The present invention provides a hemostatic bone graft product and method. Hemostatic bone grafts may include demineralized bone matrix in combination with additives. In one embodiment, the graft comprises demineralized bone and polyethylene glycol. Methods for producing the hemostatic bone graft may include mixing demineralized bone with additives to facilitate protein precipitation, surface tension reduction in blood, and/or a cytolytic effect on cells at a bleeding site.

Hemostatic bone graft

A demineralized bone matrix (DBM) or other matrix composition is provided that has been stabilized by lowering the pH of the composition, reducing the water content, adding water substitutes, and/or increasing the amount of deuterated water present in the composition in order to reduce the activity of endogenous degrading enzymes such as proteases. A hydrated form of a stabilized DBM composition may be stable up to a year at room temperature at acidic pH. The acidified DBM compositions may be further stabilized by the addition of a stabilizing agent such as deuterated water, water substitutes, polymers, protease inhibitors, glycerol or hydrogels.

Non-glycerol stabilized bone graft

Growing community of inventors

Summit, NJ, United States of America

David Knaack